Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

AegirBio: Aegirbio's Eurostar application concerning "COVID-19 detection" ranked 27th among 550 applicants

Subgen AI
Læs udgivelse

Aegirbio's application for financial aid from Eurostar concerning the project "A cost-effective and broadly applicable mimetope based diagnostic platform for high-impact pandemics" was ranked 27th among 550 applications. Aegirbio has, together with its German partner, submitted an application for part-financing of its precise COVID-19 antibody test to Eurostar. The decision whether to grant financing will be taken later.

The project aims to develop a new platform for point-of-care (POC) serology tests, with COVID-19 as the first application. Aegirbio's veritope molecules can be used to react with patients' antibodies against, for example, virus and bacteria with high precision. The molecules are relatively easy to develop and much more cost-efficient to produce in the required volumes compared with the products currently in use. Aegirbio will thus be able to adapt the fully developed platform promptly to new virus variants.

"This is conclusive evidence of our technology's performance. To be ranked 27th among 550 applications irrefutably demonstrates the strength of our technology. In this project, we see a possibility to emerge as a leader in POC testing. The precision offered by our veritope technology in combination with the superior sensitivity of the MagniaReader allows us to develop tests with high accuracy and monitor the formation of antibodies - rapdidly and at affordable production costs," says Martin Linde, CEO of Aegirbio.

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.